NO20034741L - Anvendelse av desoksypeganin for behandling av sykdomsforeteelser i det sentrale nervesystem grunnet forgiftning med psykotropiske substanser - Google Patents
Anvendelse av desoksypeganin for behandling av sykdomsforeteelser i det sentrale nervesystem grunnet forgiftning med psykotropiske substanserInfo
- Publication number
- NO20034741L NO20034741L NO20034741A NO20034741A NO20034741L NO 20034741 L NO20034741 L NO 20034741L NO 20034741 A NO20034741 A NO 20034741A NO 20034741 A NO20034741 A NO 20034741A NO 20034741 L NO20034741 L NO 20034741L
- Authority
- NO
- Norway
- Prior art keywords
- deoxypeganine
- treatment
- medicines
- substances
- poisoning
- Prior art date
Links
- WUFQLZTXIWKION-UHFFFAOYSA-N Deoxypeganine Chemical compound C1C2=CC=CC=C2N=C2N1CCC2 WUFQLZTXIWKION-UHFFFAOYSA-N 0.000 title abstract 4
- 239000000126 substance Substances 0.000 title abstract 3
- VARHXCYGZKSOOO-UHFFFAOYSA-N Deoxyvasicinone Natural products C1=CC=C2C(=O)N(CCC3)C3=NC2=C1 VARHXCYGZKSOOO-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000506 psychotropic effect Effects 0.000 title abstract 2
- 208000015114 central nervous system disease Diseases 0.000 title 1
- 231100000572 poisoning Toxicity 0.000 title 1
- 230000000607 poisoning effect Effects 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 230000001684 chronic effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 231100000614 poison Toxicity 0.000 abstract 2
- 230000002035 prolonged effect Effects 0.000 abstract 2
- 239000003440 toxic substance Substances 0.000 abstract 2
- 206010037180 Psychiatric symptoms Diseases 0.000 abstract 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 231100000570 acute poisoning Toxicity 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Oppfinnelsen er rettet mot anvendelse av deoksypeganin, som fri base eller syre addisjonssalt, for behandling av cerebrale, sentralnerve eller psykiatriske symptomer, defunksjonalisering manifestasjoner eller forstyrrelser som forekommer gjennom inntak av psykotropiske substanser, som en konsekvens av tilfeldig eller kronisk misbruk av vanedannende substanser, rusmidler eller medisiner, eller som sideeffekt av bruk, særlig gjentatt eller forlenget, som beregnet som medikamenter, eller som en effekt av bruk, særlig gjentatt eller forlenget, av medikamenter, hvilken bruk ikke er tilsiktet bruk av nevnte medikamenter, eller som et resultat av akutt forgiftning med psykotropisk toksiske substanser, eller som et resultat av kronisk eksponering for psykotropisk aktive toksiske substanser i mennesker eller andre vertebrater.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10119863A DE10119863A1 (de) | 2001-04-24 | 2001-04-24 | Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen |
| PCT/EP2002/004278 WO2002087553A2 (de) | 2001-04-24 | 2002-04-18 | Verwendung von desoxypeganin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20034741L true NO20034741L (no) | 2003-10-23 |
| NO20034741D0 NO20034741D0 (no) | 2003-10-23 |
Family
ID=7682410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034741A NO20034741D0 (no) | 2001-04-24 | 2003-10-23 | Anvendelse av desoksypeganin for behandling av sykdomsforeteelser i det sentrale nervesystem grunnet forgiftning med psykotropiske substanser |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20040132751A1 (no) |
| EP (1) | EP1383503B1 (no) |
| JP (1) | JP2004526791A (no) |
| KR (1) | KR20030094365A (no) |
| CN (1) | CN1638774A (no) |
| AR (1) | AR033469A1 (no) |
| AT (1) | ATE411024T1 (no) |
| AU (1) | AU2002325209B2 (no) |
| BR (1) | BR0209125A (no) |
| CA (1) | CA2445132C (no) |
| CZ (1) | CZ20032788A3 (no) |
| DE (2) | DE10119863A1 (no) |
| DK (1) | DK1383503T3 (no) |
| EA (1) | EA200301134A1 (no) |
| ES (1) | ES2316595T3 (no) |
| HU (1) | HUP0303921A3 (no) |
| IL (1) | IL158383A0 (no) |
| MX (1) | MXPA03009766A (no) |
| MY (1) | MY135676A (no) |
| NO (1) | NO20034741D0 (no) |
| NZ (1) | NZ529005A (no) |
| PL (1) | PL366845A1 (no) |
| PT (1) | PT1383503E (no) |
| SI (1) | SI1383503T1 (no) |
| SK (1) | SK287214B6 (no) |
| WO (1) | WO2002087553A2 (no) |
| ZA (1) | ZA200308042B (no) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10354894A1 (de) * | 2003-11-24 | 2005-07-07 | Hf Arzneimittelforschung Gmbh | Orale Formulierungen des Desoxypeganins und deren Anwendungen |
| DE10354893B4 (de) * | 2003-11-24 | 2011-03-10 | Hf Arzneimittelforschung Gmbh | Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen |
| ES2360547B1 (es) * | 2009-11-02 | 2012-07-04 | Consejo Superior De Investigaciones Científicas (Csic) | Procedimiento de obtención de los alcaloides activos de la planta medicinal peganum harmala y su uso. |
| US20220265582A1 (en) * | 2021-02-24 | 2022-08-25 | Universitätsspital Basel | Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| US3742951A (en) * | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| US3996934A (en) * | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
| US4031894A (en) * | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
| DE3315272C2 (de) * | 1983-04-27 | 1986-03-27 | Lohmann Gmbh & Co Kg, 5450 Neuwied | Pharmazeutisches Produkt und Verfahren zu seiner Herstellung |
| DE3843239C1 (no) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| US5602184A (en) * | 1993-03-03 | 1997-02-11 | The United States Of America As Represented By Department Of Health And Human Services | Monoterpenes, sesquiterpenes and diterpenes as cancer therapy |
| DE19906977C1 (de) * | 1999-02-19 | 2000-06-15 | Lohmann Therapie Syst Lts | Desoxypeganin-TTS und seine Verwendung |
| DE19906974C2 (de) * | 1999-02-19 | 2003-10-09 | Lohmann Therapie Syst Lts | Verwendung von Desoxypeganin zur Behandlung des Alkoholismus |
| DE19906975B4 (de) * | 1999-02-19 | 2004-04-15 | Lts Lohmann Therapie-Systeme Ag | Arzneiform zur Behandlung von Alzheimer'scher Demenz |
| DE19906978B4 (de) * | 1999-02-19 | 2004-07-08 | Lts Lohmann Therapie-Systeme Ag | Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit |
| DE19906979B4 (de) * | 1999-02-19 | 2004-07-08 | Lts Lohmann Therapie-Systeme Ag | Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit |
| DE19924951B4 (de) * | 1999-05-31 | 2004-02-05 | Lts Lohmann Therapie-Systeme Ag | Verwendung von Desoxypeganin zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer |
| WO2001032115A1 (en) * | 1999-11-04 | 2001-05-10 | Xel Herbaceuticals | Transdermal administration of huperzine |
-
2001
- 2001-04-24 DE DE10119863A patent/DE10119863A1/de not_active Withdrawn
-
2002
- 2002-04-18 CZ CZ20032788A patent/CZ20032788A3/cs unknown
- 2002-04-18 JP JP2002584899A patent/JP2004526791A/ja active Pending
- 2002-04-18 BR BR0209125-9A patent/BR0209125A/pt not_active IP Right Cessation
- 2002-04-18 CA CA002445132A patent/CA2445132C/en not_active Expired - Fee Related
- 2002-04-18 EP EP02758191A patent/EP1383503B1/de not_active Expired - Lifetime
- 2002-04-18 CN CNA028088891A patent/CN1638774A/zh active Pending
- 2002-04-18 DE DE50212901T patent/DE50212901D1/de not_active Expired - Lifetime
- 2002-04-18 NZ NZ529005A patent/NZ529005A/en unknown
- 2002-04-18 ES ES02758191T patent/ES2316595T3/es not_active Expired - Lifetime
- 2002-04-18 DK DK02758191T patent/DK1383503T3/da active
- 2002-04-18 US US10/475,788 patent/US20040132751A1/en not_active Abandoned
- 2002-04-18 PL PL02366845A patent/PL366845A1/xx not_active IP Right Cessation
- 2002-04-18 AU AU2002325209A patent/AU2002325209B2/en not_active Ceased
- 2002-04-18 HU HU0303921A patent/HUP0303921A3/hu unknown
- 2002-04-18 SI SI200230779T patent/SI1383503T1/sl unknown
- 2002-04-18 AT AT02758191T patent/ATE411024T1/de not_active IP Right Cessation
- 2002-04-18 SK SK1316-2003A patent/SK287214B6/sk not_active IP Right Cessation
- 2002-04-18 MX MXPA03009766A patent/MXPA03009766A/es active IP Right Grant
- 2002-04-18 PT PT02758191T patent/PT1383503E/pt unknown
- 2002-04-18 WO PCT/EP2002/004278 patent/WO2002087553A2/de not_active Ceased
- 2002-04-18 IL IL15838302A patent/IL158383A0/xx not_active IP Right Cessation
- 2002-04-18 EA EA200301134A patent/EA200301134A1/ru unknown
- 2002-04-18 KR KR10-2003-7013972A patent/KR20030094365A/ko not_active Ceased
- 2002-04-22 MY MYPI20021470A patent/MY135676A/en unknown
- 2002-04-24 AR ARP020101483A patent/AR033469A1/es unknown
-
2003
- 2003-10-16 ZA ZA200308042A patent/ZA200308042B/en unknown
- 2003-10-23 NO NO20034741A patent/NO20034741D0/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9908488A (pt) | Composição farmacêutica de topiramato | |
| PT1066036E (pt) | Agentes com actividade relacionada com serotonina para o tratamento da apneia do sono | |
| NO20045323L (no) | Antistoffer | |
| BRPI0518266B8 (pt) | medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular | |
| BR0008447A (pt) | Métodos de tratamento de distúrbios mitocondriais | |
| CY1118311T1 (el) | Παραγωγα νιτροκατεχολης ως αναστολεις comt που χορηγουνται με ειδικη αγωγη δοσολογιας | |
| UY26320A1 (es) | Sales farmaceuticas de la sustancia activa tramadol y al menos un edulcorante, medicamentos que contienen estas sales, el uso de estas sales para la preparacion de medicamentos y formas de administracion que contienen esas sales. ley 17164 | |
| BR0308290A (pt) | Tratamento e prevenção de distúrbios inflamatórios | |
| NO20060871L (no) | Azepinderivater som farmasoytiske midler | |
| BR9811093A (pt) | Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo) | |
| SI2413933T1 (en) | 2,4,6-TRIUFLORO-N- (6- (1-METHYL-PIPERIDIN-4-CARBONYL) -PYRIDIN-2-YL)-BENZAMIDE FOR THRESHOLD OF MIGRINE OVER ORAL OR INTRAVEN | |
| TR200402275T2 (tr) | Nörotik düzensizliklerin tedavisi | |
| NO20034741L (no) | Anvendelse av desoksypeganin for behandling av sykdomsforeteelser i det sentrale nervesystem grunnet forgiftning med psykotropiske substanser | |
| Oh et al. | Lowering the seizure threshold associated with antidepressants, stimulants, antipsychotics, and others | |
| ATE234082T1 (de) | Adenosin enthaltendes arzneimittel | |
| EP1426360A4 (en) | 2-PHENYL-3-HETEROARYLPROPIONIC ACID DERIVATIVE OR SALT THEREOF AND MEDICAMENTS CONTAINING THE SAME | |
| BR0010006A (pt) | Utilização do saredutante e de seus sais farmaceuticamente aceitáveis para o preparo de medicamentos úteis no tratamento ou na prevenção do conjunto das perturbações do humor, das perturbações da adaptação ou das perturbações mistas ansiedade-depressão | |
| BRPI0407438A (pt) | Sistema terapêutico compreendendo amoxicilina e ácido clavulânico | |
| NO953892D0 (no) | Imidazolokinoksalinon-derivater som EAA-antagonister | |
| Angley et al. | Children and autism: Part 2-management with complementary medicines and dietary interventions | |
| NO20034740D0 (no) | Anvendelse av galantamin for behandling av patologiske manifestasjoner i sentralnervesystemet grunnet forgiftning med psykotropiskesubstanser | |
| RU94032792A (ru) | Применение 5нтiа - антагонистов для прекращения использования табака | |
| JP2004526791A5 (no) | ||
| BRPI0601285A (pt) | uso de agomelatina na obtenção de medicamentos destinados ao tratamento de distúrbios bipolares | |
| EA200500538A1 (ru) | Фармацевтическое средство для эндоназального применения при лечении болезней и нарушений нервной системы |